Paper Details

  1. Home
  2. Paper Details

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.

Author: ArnulfBertrand, BaronLudivine, BoriesJean-Christophe, ChoisyCaroline, DadaglioGilles, DemangelCaroline, DerianoLudovic, DomengerAntoine, MayauVéronique, PerthameEmeline

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the use of mycolactone, a Sec61 inhibitor, for the treatment of multiple myeloma (MM). Mycolactone effectively disrupted MM proteostasis, leading to cell death and overcoming drug resistance. A combination of mycolactone and bortezomib showed superior therapeutic efficacy over single-drug treatments in immunodeficient mice engrafted with MM cells.
Paper Details　
Original Abstract of the Article :
Multiple myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression, drug resistance inevitably develop, and novel therapeutic approaches are needed. Here, we used...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899908/

データ提供：米国国立医学図書館（NLM）

Targeting the Sec61 Translocon: A New Oasis in the Desert of Multiple Myeloma

Multiple myeloma (MM) is a formidable foe, like a vast and unforgiving desert. This research explores a novel therapeutic approach to combatting this deadly disease, focusing on the Sec61 translocon, a key protein involved in protein translocation. The authors, like skilled desert explorers, investigate the effects of mycolactone, a Sec61 inhibitor, on MM cell lines, revealing its ability to disrupt proteostasis and induce cell death. Their findings suggest that targeting the Sec61 translocon may offer a promising new weapon in the fight against MM.

A New Path Through the Desert of MM

This research presents a promising new avenue for MM treatment, targeting the Sec61 translocon with the Sec61 inhibitor mycolactone. The results demonstrate its ability to disrupt proteostasis and induce MM cell death, offering a potential oasis of hope for patients facing this challenging disease.

A Multi-Pronged Approach to MM Treatment

The study emphasizes the importance of a multi-pronged approach to MM treatment, combining traditional therapies with novel strategies like targeting the Sec61 translocon. It's like navigating a complex desert landscape – you must utilize different tools and approaches to ensure success.

Dr.Camel's Conclusion

This research opens a new chapter in the fight against multiple myeloma, revealing the potential of targeting the Sec61 translocon with mycolactone. It's like finding a new oasis in the vast desert of MM research. This promising approach, combined with existing therapies, may offer a new hope for patients grappling with this devastating disease.

Date :
  1. Date Completed 2022-03-14
  2. Date Revised 2022-03-14
Further Info :

Pubmed ID

35014767

DOI: Digital Object Identifier

PMC8899908

Related Literature

Article Analysis
・Side Effects of bortezomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.